Important: Ceritinib 150 mg is a targeted anticancer medicine used in selected patients with ALK-positive non-small cell lung cancer. Treatment requires confirmation of ALK-positive tumor status, specialist supervision and monitoring for potentially serious adverse effects.
Strength clarification: The 150 mg strength refers to the amount of ceritinib in an individual capsule or tablet. It does not necessarily represent the complete daily dose. Under current US labeling, the usual adult dose is 450 mg once daily with food, equivalent to three 150 mg units. Other approved formulations and regional prescribing instructions must be verified.
What Is Ceritinib 150 mg?
Ceritinib 150 mg is an oral targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class.
It is primarily used to treat selected patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors are positive for anaplastic lymphoma kinase (ALK) gene rearrangements.
ALK is a receptor tyrosine kinase involved in cellular growth and signaling.
In certain lung cancers, rearrangements involving the ALK gene produce abnormal fusion proteins that continuously activate signaling pathways responsible for cancer cell growth and survival.
One of the most common ALK rearrangements in NSCLC is the EML4-ALK fusion.
These abnormal proteins can stimulate cancer cell proliferation and contribute to tumor development.
Ceritinib works by inhibiting ALK tyrosine kinase activity, thereby interfering with signals that promote cancer cell growth.
Ceritinib is generally classified as a second-generation ALK inhibitor.
It was developed to target ALK-driven cancers and has demonstrated activity in selected patients, including some whose disease progressed after earlier ALK-targeted treatment.
However, the effectiveness of ceritinib depends on the tumor’s molecular characteristics, previous therapies and resistance mechanisms.
Unlike conventional cytotoxic chemotherapy, ceritinib is designed to inhibit a specific molecular target associated with certain cancers.
Nevertheless, it can cause significant adverse effects, particularly gastrointestinal problems, liver toxicity, changes in blood glucose, heart rhythm abnormalities and rare lung inflammation.
Important: Ceritinib is not suitable for all types of lung cancer. ALK-positive status must be established using an appropriate diagnostic test before treatment is initiated.
How Does Ceritinib 150 mg Work?
1. Targets ALK Tyrosine Kinase
Ceritinib inhibits the activity of anaplastic lymphoma kinase, a protein involved in cellular signaling.
2. Blocks Abnormal ALK Signaling
Certain ALK gene rearrangements produce abnormal proteins that continuously stimulate cancer cell growth.
Ceritinib interferes with these abnormal signals.
3. Inhibits Cancer Cell Proliferation
By blocking ALK signaling, ceritinib can reduce the proliferation of susceptible cancer cells.
4. Suppresses Downstream Signaling Pathways
ALK inhibition can affect intracellular pathways involved in cancer cell growth and survival, including PI3K/AKT and MAPK-related signaling.
5. Promotes Cancer Cell Death
In susceptible ALK-dependent cancer cells, inhibition of signaling may promote apoptosis.
6. Helps Control Tumor Growth
Ceritinib may reduce tumor size or delay disease progression in appropriately selected patients.
7. Provides Molecularly Targeted Therapy
Its clinical effectiveness depends substantially on the presence of an ALK alteration that remains sensitive to ceritinib.
8. Offers Activity Against Certain Resistance Mutations
Ceritinib may retain activity against some ALK resistance mutations associated with earlier ALK inhibitors.
However, it does not overcome every resistance mechanism.
Important: ALK mutation profiles and treatment history influence the selection of ceritinib or alternative ALK-targeted medicines.
Uses of Ceritinib 150 mg
1. ALK-Positive Non-Small Cell Lung Cancer
Ceritinib is used for selected patients with ALK-positive NSCLC.
The presence of an ALK gene rearrangement must be confirmed through appropriate testing.
2. Metastatic ALK-Positive NSCLC
Ceritinib has an established indication for ALK-positive metastatic non-small cell lung cancer in certain jurisdictions.
3. Advanced ALK-Positive Lung Cancer
Ceritinib may be prescribed for advanced disease when ALK-directed therapy is clinically appropriate.
4. Molecularly Targeted Lung Cancer Treatment
Ceritinib targets abnormal ALK signaling rather than acting as conventional nonspecific cytotoxic chemotherapy.
5. Selected Patients With Previous ALK Inhibitor Exposure
Ceritinib has demonstrated activity in some patients previously treated with crizotinib.
However, treatment selection depends on prior therapy, resistance mutations and currently available alternatives.
6. First-Line Treatment in Certain Approved Settings
Ceritinib has been approved for treatment of ALK-positive metastatic NSCLC without requiring prior ALK inhibitor treatment.
Newer ALK inhibitors are often preferred in current treatment guidelines because of differences in efficacy, central nervous system activity and tolerability.
7. ALK-Driven Tumor Growth Control
Ceritinib may help reduce or stabilize tumor growth when the cancer remains susceptible to ALK inhibition.
8. Treatment of Selected Patients With Brain Metastases
Ceritinib has demonstrated intracranial activity in some patients with ALK-positive NSCLC and brain metastases.
However, treatment choice depends on central nervous system disease characteristics and the availability of other ALK inhibitors.
9. Individualized Oncology Treatment
Ceritinib may be selected based on ALK testing, prior therapies, treatment tolerance and clinical assessment.
10. Long-Term Disease Management
When effective and tolerated, ceritinib may be continued to help control cancer progression.
Important: Ceritinib is not approved for every type of lung cancer, and it should not be advertised as a universal cancer treatment.
How to Take Ceritinib 150 mg
Ceritinib must be taken strictly according to the oncology specialist’s prescription.
General Administration Instructions
- Confirm the prescribed strength and dosage schedule.
- Take ceritinib at approximately the same time each day.
- Follow the food instructions for the specific formulation and approved regimen.
- Under current US labeling, take ceritinib with food.
- Swallow the capsule or tablet whole.
- Do not independently increase, decrease or interrupt the dose.
- Do not take additional doses to compensate for a missed dose.
- Report severe gastrointestinal symptoms or unusual weakness promptly.
- Attend scheduled laboratory tests and oncology appointments.
- Follow any prescribed dose interruption or reduction plan.
Dosage Information
| Dosage Detail | General Guidance |
|---|---|
| Individual Unit Strength | 150 mg |
| Route | Oral |
| Typical Adult Dose Under Current US Labeling | 450 mg Once Daily With Food |
| Number of 150 mg Units at 450 mg Dose | Three |
| Administration Frequency | Once Daily |
| Food Requirement | With Food Under Current US Labeling |
| Treatment Duration | Until Disease Progression or Unacceptable Toxicity |
| Dose Adjustment | Based on Adverse Effects, Drug Interactions and Clinical Assessment |
| Missed Dose | Follow Product-Specific Instructions |
| Monitoring | Liver Function, Blood Glucose, ECG, Electrolytes and Other Tests as Indicated |
Important: Earlier ceritinib regimens used 750 mg once daily under fasting conditions. The 450 mg once-daily regimen with food is the standard under current US labeling. These regimens should not be interchanged without specialist guidance.
Is Ceritinib 150 mg Taken Once Daily?
Ceritinib is generally administered once daily.
However, the prescribed daily dose may require multiple 150 mg units.
Should Ceritinib Be Taken With Food?
Under current US labeling, ceritinib is taken with food.
Patients should follow the instructions for their specific product and country.
Can Ceritinib Be Taken at Night?
Ceritinib may be taken at a consistent time that follows the prescribed food instructions.
Can Ceritinib Capsules Be Opened?
Ceritinib capsules should generally be swallowed whole.
Do not open, crush or chew them unless the product labeling and oncology team specifically authorize an alternative method.
What If a Dose Is Missed?
Under current US labeling, a missed dose should be taken when remembered unless the next dose is due within 12 hours.
If the next dose is within 12 hours, skip the missed dose.
Do not double the dose.
What If Vomiting Occurs After Taking Ceritinib?
Do not take an additional dose to replace the vomited dose.
Continue with the next scheduled dose unless the oncology team advises otherwise.
What If Too Much Ceritinib Is Taken?
An overdose may cause serious adverse effects.
Seek urgent medical attention.
How Long Does Ceritinib 150 mg Take to Work?
The response to ceritinib depends on the cancer’s molecular characteristics, disease burden and individual treatment response.
After Administration
Ceritinib is absorbed and begins inhibiting susceptible ALK signaling pathways.
During the First Several Weeks
Biological effects on ALK-dependent cancer cells may occur.
During Early Treatment Assessment
Imaging studies may demonstrate tumor shrinkage or disease stabilization.
During Continued Treatment
The oncology team evaluates treatment response, adverse reactions and possible disease progression.
Important: Treatment effectiveness must be assessed through clinical evaluation and imaging rather than symptoms alone.
Common Side Effects
Possible side effects include:
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Reduced appetite
- Fatigue
- Weight loss
- Constipation
- Elevated liver enzymes
- Increased blood glucose
- Increased creatinine
- Skin rash
- Changes in laboratory results
Gastrointestinal adverse effects are particularly common and may require supportive treatment, dose interruption or dose reduction.
Serious Side Effects
Seek urgent medical attention if any of the following occur:
- Severe or persistent vomiting
- Severe diarrhea
- Significant dehydration
- Yellowing of the skin or eyes
- Dark urine
- Severe abdominal pain
- New or worsening breathing difficulties
- Persistent cough with fever
- Fainting
- Irregular heartbeat
- Severe dizziness
- Symptoms of markedly elevated blood glucose
- Severe weakness
- Significant reduction in urine output
Important Serious Risks
Hepatotoxicity: Ceritinib can cause serious liver injury, including rare fatal cases.
Interstitial Lung Disease: Rare but potentially fatal interstitial lung disease or pneumonitis may occur.
QT Interval Prolongation: Ceritinib may prolong the QT interval and increase the risk of serious cardiac rhythm abnormalities.
Bradycardia: Ceritinib can cause a slow heart rate, which may become clinically significant.
Hyperglycemia: Ceritinib can cause significant elevations in blood glucose, particularly in patients with diabetes.
Pancreatitis: Pancreatitis, including serious cases, has been reported.
Severe Gastrointestinal Toxicity: Persistent diarrhea, nausea or vomiting may cause dehydration and require treatment interruption.
Embryo-Fetal Toxicity: Ceritinib can harm a developing fetus.
Contraindications & Precautions
1. Allergy to Ceritinib
Patients with known serious hypersensitivity to ceritinib or formulation ingredients should not use the medicine.
2. ALK Testing
ALK-positive tumor status should be confirmed before initiating ALK-directed treatment.
3. Liver Disease
Patients with liver impairment require careful evaluation and monitoring.
4. Severe Hepatotoxicity
Ceritinib can cause serious liver injury.
Liver function testing is required before treatment and regularly during therapy.
5. Interstitial Lung Disease
New or worsening respiratory symptoms require immediate medical evaluation.
6. QT Interval Prolongation
Patients with QT prolongation, electrolyte abnormalities or relevant cardiac conditions may require additional monitoring.
7. Bradycardia
Ceritinib may cause a slow heart rate.
Patients taking other heart-rate-lowering medicines require careful assessment.
8. Hyperglycemia
Blood glucose should be monitored before and during treatment.
Patients with diabetes may require changes to their glucose-lowering treatment.
9. Pancreatitis
Patients experiencing severe abdominal pain, particularly with vomiting, should seek medical attention.
10. Gastrointestinal Toxicity
Severe diarrhea, nausea or vomiting may require supportive care or dose modification.
11. Kidney Function
Renal function may require monitoring, particularly in patients experiencing dehydration.
12. Pregnancy
Ceritinib can cause fetal harm and should generally be avoided during pregnancy.
13. Breastfeeding
Breastfeeding is not recommended during treatment and for the period specified in the product labeling after the final dose.
14. Drug Interactions
Ceritinib is affected by CYP3A-related drug interactions.
Important examples include:
- Ketoconazole
- Itraconazole
- Clarithromycin
- Rifampicin
- Carbamazepine
- Phenytoin
- St. John’s wort
- Certain medicines that prolong the QT interval
- Certain medicines that slow heart rate
Ceritinib may also affect exposure to other medicines metabolized through relevant enzyme pathways.
15. Grapefruit Products
Grapefruit and grapefruit juice should generally be avoided because they can increase ceritinib exposure.
16. Medication Adherence
Consistent dosing is important for maintaining treatment exposure.
17. Dose Adjustment
Dose interruption or reduction may be required because of toxicity or certain drug interactions.
18. Medical Monitoring
Healthcare professionals may assess:
- ALK-positive tumor status
- Cancer stage
- Treatment response
- Imaging findings
- Liver function
- Blood glucose
- Kidney function
- Electrolyte levels
- ECG findings
- QT interval
- Heart rate
- Pancreatic enzymes when indicated
- Gastrointestinal symptoms
- Hydration status
- Respiratory symptoms
- Nutritional status
- Weight changes
- Medication interactions
- Need for dose interruption
- Need for dose reduction
- Disease progression
Potential Therapeutic Advantages
- Targeted Anticancer Activity.
- ALK Tyrosine Kinase Inhibition.
- ALK-Positive NSCLC Treatment.
- Molecularly Guided Therapy.
- Oral Administration.
- Once-Daily Dosing.
- Activity Against Selected ALK Resistance Mutations.
- Potential Tumor Growth Control.
- Activity in Certain Previously Treated Patients.
- Demonstrated Intracranial Activity in Selected Patients.
- 150 mg Unit Strength.
- Dose Adjustment Flexibility.
- Specialist-Directed Long-Term Treatment.
Disadvantages / Limitations
- Not Suitable for ALK-Negative Lung Cancer.
- Requires ALK Testing.
- May Cause Severe Nausea.
- May Cause Vomiting.
- May Cause Diarrhea.
- May Cause Abdominal Pain.
- May Cause Reduced Appetite.
- May Cause Weight Loss.
- May Cause Liver Injury.
- May Cause Hyperglycemia.
- May Cause QT Interval Prolongation.
- May Cause Bradycardia.
- May Cause Pancreatitis.
- Rare Interstitial Lung Disease Risk.
- Potential Kidney Complications.
- Significant Drug Interaction Potential.
- Grapefruit Restriction.
- Pregnancy-Related Harm.
- Requires Regular Laboratory Monitoring.
- May Require Dose Reduction.
- Cancer May Develop Treatment Resistance.
- Does Not Guarantee a Cure.
Important Notes
Generic Name: Ceritinib.
Strength: 150 mg.
Drug Class: Tyrosine Kinase Inhibitor.
Therapeutic Category: Targeted Anticancer Medicine.
Mechanism of Action: ALK Tyrosine Kinase Inhibition.
Primary Indication: ALK-Positive Metastatic NSCLC.
Route: Oral.
Typical US-Labeled Adult Dose: 450 mg Once Daily With Food.
150 mg Strength: Individual Capsule or Tablet Strength.
Major Warning: Hepatotoxicity.
Lung Warning: Interstitial Lung Disease Risk.
Heart Monitoring: QT Interval and Heart Rate.
Blood Glucose Monitoring: Important.
Pancreatitis Risk: Important.
Grapefruit: Avoid.
Pregnancy: Can Cause Fetal Harm.
Breastfeeding: Not Recommended During Treatment.
Medical Supervision: Oncology Specialist Required.
Storage: Follow Manufacturer Instructions.
Frequently Asked Questions
1. What is Ceritinib 150 mg used for?
Ceritinib is used to treat selected patients with ALK-positive metastatic non-small cell lung cancer.
2. Is Ceritinib a chemotherapy medicine?
Ceritinib is a targeted anticancer medicine classified as a tyrosine kinase inhibitor. It differs from conventional cytotoxic chemotherapy.
3. How does Ceritinib work?
Ceritinib inhibits ALK tyrosine kinase activity and interferes with signaling pathways that promote cancer cell growth.
4. Is Ceritinib used for lung cancer?
Yes. Ceritinib is used for selected ALK-positive non-small cell lung cancers.
5. Does Ceritinib require ALK testing?
Yes. ALK-positive tumor status must be established before ALK-directed treatment.
6. Is Ceritinib 150 mg the standard daily dose?
No. The 150 mg strength refers to an individual unit. Under current US labeling, the usual adult dose is 450 mg once daily with food.
7. Can Ceritinib be taken daily?
Yes. Ceritinib is generally administered once daily according to the oncology prescription.

































































